https://www.selleckchem.com/pr....oducts/anacardic-aci
Background Radioiodine-refractory differentiated thyroid cancer (RR-DTC) has a low 10-year patient-survival rate and is challenging to treat. Lenvatinib is a multikinase inhibitor approved for the treatment of RR-DTC. This study aims to assess Eastern Cooperative Oncology Group performance status (ECOG PS) and neutrophil-to-lymphocyte ratio (NLR) as prognostic markers for patients with RR-DTC treated with lenvatinib. Methods In this retrospective analysis of the Study of (E708 LEnvatinib in Differentiated Cancer of the Thyroid
Like
Comment
Share
